BMS buys into AI-designed immune drug from Exscientia

Bristol Myers Squibb has exercised an option on an immune-modulating drug candidate developed by UK artificial intelligence specialist Exscientia, paying $20 million for the buy-in as part of their $1.2 billion alliance.

The unnamed drug candidate acts on an immunological kinase enzyme, which has proven hard to target using conventional drug discovery techniques because challenges relating to “potency, selectivity, and overall drug-like properties,” according to the partners.

Read the source article at pharmaphorum.com
2021-08-20 10:49:02